RecruitingPhase 1NCT07270783
Healthy Volunteer Study
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects
Sponsor
InventisBio Co., Ltd
Enrollment
36 participants
Start Date
Dec 4, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria1
- Healthy volunteer subjects meeting eligibility criteria
Exclusion Criteria3
- Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
- Subjects with a history of drug and alcohol abuse
- Subjects taking medications, over the counter or herbal remedies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGD-2570
D-2570
DRUGPlacebo
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07270783
Related Trials
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
NCT062747491 location
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
NCT056524781 location
Collection of Data and Samples From Healthy Donors for Use in Translational Research
NCT000906621 location
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
NCT015686971 location